Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07369024
PHASE2

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Sponsor: Mohsen Saidinejad

View on ClinicalTrials.gov

Summary

The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.

Official title: Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults: A Randomized Control Trial

Key Details

Gender

All

Age Range

5 Years - 20 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-04-01

Completion Date

2028-04-30

Last Updated

2026-03-09

Healthy Volunteers

No

Interventions

DRUG

Sub-dissociative Ketamine Infusion

0.25 mg/kg of IV ketamine within a 20-minute infusion of 100 milliliters of normal saline (NS)

DRUG

Normal Saline Placebo Infusion

20-minute infusion of 100 milliliters of normal saline

Locations (1)

Harbor UCLA Medical Center

Torrance, California, United States